NCT02561494

Brief Summary

Nefopam will be administered to the patients undergoing laparoscopic gastrectomy under the total intravenous anesthesia (TIVA). The investigators will evaluate whether the nefopam can decrease the total amount of remifentanil administered during the operation, which will reduce the acute opioid tolerance and following consumption of fentanyl during postoperative period.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
78

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2015

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2015

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

August 2, 2015

Completed
2 months until next milestone

First Posted

Study publicly available on registry

September 28, 2015

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2016

Completed
Last Updated

October 28, 2016

Status Verified

October 1, 2016

Enrollment Period

1.2 years

First QC Date

August 2, 2015

Last Update Submit

October 27, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change of the administered fentanyl dose from postoperative 6 h to postoperative 5 day

    postoperative 6 h, postoperative 1 day, postoperative 2 day, postoperative 3 day, postoperative 5 day

Secondary Outcomes (1)

  • Change of the pain score from postoperative 6 h to postoperative 5 day

    postoperative 6 h, postoperative 1 day, postoperative 2 day, postoperative 3 day, postoperative 5 day

Study Arms (2)

Control

PLACEBO COMPARATOR

Intravenous normal saline 2 ml is given slowly as a placebo before the anesthesia induction and after finishing anesthesia.

Drug: Saline

Nefopam

EXPERIMENTAL

Intravenous nefopam 20 mg is given slowly before the anesthesia induction and after finishing anesthesia.

Drug: Nefopam

Interventions

Nefopam
SalineDRUG
Control

Eligibility Criteria

Age20 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Early or advanced gastric cancer

You may not qualify if:

  • Refusal
  • Use of preoperative analgesic drugs
  • Pregnancy
  • Recurred gastric cancer
  • Seizure
  • Cardiac disease
  • Monoamine oxidase inhibitor
  • Urologic disease
  • Previous intrabdominal surgery
  • Body mass index \> 30 or \< 16

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, 443-607, South Korea

Location

MeSH Terms

Conditions

Stomach Neoplasms

Interventions

NefopamSodium Chloride

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesStomach Diseases

Intervention Hierarchy (Ancestors)

OxazocinesAzocinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

August 2, 2015

First Posted

September 28, 2015

Study Start

June 1, 2015

Primary Completion

August 1, 2016

Study Completion

August 1, 2016

Last Updated

October 28, 2016

Record last verified: 2016-10

Locations